針對新型冠狀病毒肺炎患者的霧化吸入治療的建議_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

倪忠 ¹ ^* , 羅鳳鳴 ¹ ^* , 王吉梅 ² , 劉婷婷 ¹ , 張婷夏 ¹ , 楊薇 ¹ , 王乙茹 ¹ , 徐智 ³ , 張偉 ⁴ , 王勝昱 ⁵ , 代冰 ⁶ , 李潔 ⁷ ,  葛慧青 ² ,  梁宗安；中華醫學會呼吸病學分會呼吸治療學組

1. ;
2. ;
3. ;
4. ;
5. ;
6. ;
7. ;

Corresponding?author：

葛慧青, Email: gehq@zhu.edu.cn; 梁宗安；中華醫學會呼吸病學分會呼吸治療學組, Email: liangza@scu.edu.cn

Keywords：

DOI：

10.7507/1671-6205.202002006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 倪忠, 羅鳳鳴, 王吉梅, 劉婷婷, 張婷夏, 楊薇, 王乙茹, 徐智, 張偉, 王勝昱, 代冰, 李潔, 葛慧青, 梁宗安；中華醫學會呼吸病學分會呼吸治療學組. 針對新型冠狀病毒肺炎患者的霧化吸入治療的建議. Chinese Journal of Respiratory and Critical Care Medicine, 2020, 19(2): 120-124. doi: 10.7507/1671-6205.202002006 Copy

1.	國家衛生健康委辦公廳國家中醫藥管理局辦公室《新型冠狀病毒感染的肺炎診療方案 (試行第五版)》.http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
2.	中華醫學會呼吸病學分會呼吸治療學組. 機械通氣時霧化吸入專家共識 (草案). 中華結核和呼吸雜志, 2014, 37(11): 812-815.
3.	中華醫學會臨床藥學分會. 霧化吸入療法合理用藥專家共識 (2019 年版). 醫藥導報, 2019, 38(2): 135-146.
4.	中華醫學會呼吸病學分會《霧化吸入療法在呼吸疾病中的應用專家共識》制定專家組. 霧化吸入療法在呼吸疾病中的應用專家共識. 中華醫學雜志, 2016, 96(34): 2696-2708.
5.	中國醫師協會急診醫師分會. 霧化吸入療法急診臨床應用專家共識 (2018). 中國急救醫學, 2018, 38(7): 565-575.
6.	洪建國, 陳強, 陳志敏, 等. 兒童常見呼吸道疾病霧化吸入治療專家共識. 中國實用兒科雜志, 2012, 27(4): 265-269.
7.	俞森洋. 現代呼吸治療學. 上海: 科學技術文獻出版社, 2006.
8.	雷婷婷, 趙榮生. 霧化吸入給藥的臨床應用現狀及研究進展. 臨床藥物治療雜志, 2016, 14(3): 1-5.
9.	Vassal S, Taamma R, Marty N, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control, 2000, 28(5): 347-351.
10.	Gamage B, Moore D, Copes R, et al. Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature. Am J Infect Control, 2005, 33(2): 114-121.
11.	Hamill RJ, Houston ED, Georghiou PR, et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med, 1995, 122(10): 762-766.
12.	Tablan OC, Anderson LJ, Besser R, et al. Guidelines for Preventing Health Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep, 2004, 53: 1-36.
13.	Wilkinson JR, Roberts JA, Bradding P, et al. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ, 1992, 305(6859): 931-932.
14.	Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care, 2008, 53(6): 699-725.
15.	Dimich-Ward H, Wymer ML, Chan-Yeung M. Respiratory health survey of respiratory therapists. Chest, 2004, 126(4): 1048-1053.
16.	Christiani DC, Kern DG. Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis, 1993, 148(3): 671-674.

1. 國家衛生健康委辦公廳國家中醫藥管理局辦公室《新型冠狀病毒感染的肺炎診療方案 (試行第五版)》.http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
2. 中華醫學會呼吸病學分會呼吸治療學組. 機械通氣時霧化吸入專家共識 (草案). 中華結核和呼吸雜志, 2014, 37(11): 812-815.
3. 中華醫學會臨床藥學分會. 霧化吸入療法合理用藥專家共識 (2019 年版). 醫藥導報, 2019, 38(2): 135-146.
4. 中華醫學會呼吸病學分會《霧化吸入療法在呼吸疾病中的應用專家共識》制定專家組. 霧化吸入療法在呼吸疾病中的應用專家共識. 中華醫學雜志, 2016, 96(34): 2696-2708.
5. 中國醫師協會急診醫師分會. 霧化吸入療法急診臨床應用專家共識 (2018). 中國急救醫學, 2018, 38(7): 565-575.
6. 洪建國, 陳強, 陳志敏, 等. 兒童常見呼吸道疾病霧化吸入治療專家共識. 中國實用兒科雜志, 2012, 27(4): 265-269.
7. 俞森洋. 現代呼吸治療學. 上海: 科學技術文獻出版社, 2006.
8. 雷婷婷, 趙榮生. 霧化吸入給藥的臨床應用現狀及研究進展. 臨床藥物治療雜志, 2016, 14(3): 1-5.
9. Vassal S, Taamma R, Marty N, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control, 2000, 28(5): 347-351.
10. Gamage B, Moore D, Copes R, et al. Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature. Am J Infect Control, 2005, 33(2): 114-121.
11. Hamill RJ, Houston ED, Georghiou PR, et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med, 1995, 122(10): 762-766.
12. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for Preventing Health Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep, 2004, 53: 1-36.
13. Wilkinson JR, Roberts JA, Bradding P, et al. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ, 1992, 305(6859): 931-932.
14. Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care, 2008, 53(6): 699-725.
15. Dimich-Ward H, Wymer ML, Chan-Yeung M. Respiratory health survey of respiratory therapists. Chest, 2004, 126(4): 1048-1053.
16. Christiani DC, Kern DG. Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis, 1993, 148(3): 671-674.

Previous Article
新型冠狀病毒肺炎患者呼吸機使用感控管理專家共識
Next Article
新型冠狀病毒肺炎診治的實驗室檢驗路徑探討

Chinese Journal of Respiratory and Critical Care Medicine

針對新型冠狀病毒肺炎患者的霧化吸入治療的建議

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content